Puma Biotechnology Inc (PBYI) financials
Puma Biotechnology revenue and earnings by year
Puma Biotechnology's revenue was $228 million in the fiscal year to December 31, 2025, down 0.9% from the year before. Net income was $31.1 million, 13.6% of revenue. Since the fiscal year to December 31, 2017, revenue has grown 30.2% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 9 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 228 | 230 | 236 | 228 | 253 | 225 | 272 | 251 | 28 |
| Revenue growth | -0.9% | -2.2% | 3.3% | -9.9% | 12.5% | -17.3% | 8.5% | 806.6% | — |
| Gross profit | 170 | 166 | 173 | 173 | 189 | 186 | 235 | 216 | 22 |
| Gross margin | 74.5% | 72.1% | 73.4% | 75.8% | 74.8% | 82.5% | 86.5% | 86.2% | 79.9% |
| Operating income | 37 | 31 | 33 | 24 | 1 | -30 | -39 | -95 | -292 |
| Operating margin | 16.3% | 13.4% | 13.9% | 10.4% | 0.5% | -13.5% | -14.3% | -37.7% | -1056.1% |
| Net income | 31 | 30 | 22 | 0 | -29 | -60 | -76 | -114 | -292 |
| Net margin | 13.6% | 13.1% | 9.2% | 0.0% | -11.5% | -26.7% | -27.8% | -45.3% | -1054.6% |
| Diluted EPS | $0.61 | $0.62 | $0.45 | $0.00 | -$0.72 | -$1.52 | -$1.95 | -$2.99 | -$7.84 |
| Free cash flow | 42 | 39 | 27 | -16 | 21 | 1 | 22 | -25 | -173 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open PBYI in Markets.
How Puma Biotechnology makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Product | $53.6M | 94.8% |
| Royalty | $2.94M | 5.2% |
See also: PBYI valuation and P/E history · PBYI returns
No forecast, no recommendation. This page describes Puma Biotechnology Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.